Search

Your search keyword '"Huang, Shi’An"' showing total 22 results

Search Constraints

Start Over You searched for: Author "Huang, Shi’An" Remove constraint Author: "Huang, Shi’An"
22 results on '"Huang, Shi’An"'

Search Results

1. Ultra-high Performance Liquid Chromatography-Tandem Mass Spectrometry-Based Metabolomic Analysis of Primary Metabolites in ‘Fengtang’ Plum Fruits from Different Geographical Origins

2. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

3. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

6. Heart‑lung crosstalk in pulmonary arterial hypertension following myocardial infarction (Review)

7. Acute conduction recurrence of mitral isthmus: Incidence, clinical characteristics, and implications

8. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

9. Baicalin prevents pulmonary arterial remodeling in vivo via the AKT/ERK/NF-κB signaling pathways

10. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

11. Quercetin Inhibits Pulmonary Arterial Endothelial Cell Transdifferentiation Possibly by Akt and Erk1/2 Pathways

12. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

13. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

14. Aryl Hydrocarbon Receptor: A New Player of Pathogenesis and Therapy in Cardiovascular Diseases

15. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

16. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

17. Occurrence of composite cardiac endpoints with change in resting heart rate among Chinese patients with coronary artery disease: Chinese cohort from the real-world BISO-CAD study

18. Transfer of human hepatocyte growth factor reduces inflammation and prevents pulmonary arterial remodeling in monocrotaline-induced

20. Research on Product Innovative Design Method Driven by Client Demands.

21. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

22. Transfer of human hepatocyte growth factor reduces inflammation and prevents pulmonary arterial remodeling in monocrotaline-induced.

Catalog

Books, media, physical & digital resources